|
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Leiden, The Netherlands, 11 October 2000 - Crucell N.V. today filed a registration statement with the U.S. Securities and Exchange Commission in connection with its proposed global offering of ordinary shares. Crucell expects the offering to consist of a public offering of ordinary shares to retail and institutional investors in The Netherlands, an offering of ordinary shares to institutional investors outside The Netherlands and an offering of ordinary shares in the United States. The ordinary shares are being offered in the form of ordinary shares or American Depositary Shares (ADSs). Each ADS will represent one ordinary share.
Crucell intends to offer up to 9,200,000 newly issued ordinary shares (including the underwriters' over-allotment option) in the form of ordinary shares or ADSs. Crucell currently estimates that the initial public offering price per ordinary share will be between €17.00 and €20.50. This is equivalent to a price range of $14.76 to $17.79 per ADS at an exchange rate of €1.00 = $0.8680. All shares are being offered by the company, which expects to receive all proceeds of the offering (less expenses); this represents new financing for the company. Crucell has applied to list the ADSs on the Nasdaq National Market and the Official Market of the stock market of Euronext (Amsterdam).
Crucell is a biotechnology company formed through the merger of IntroGene B.V. and U-BiSys B.V., both from The Netherlands. Crucell combines IntroGene's human cell line platform, PER.C6, with U-BiSys' subtractive phage antibody-display selection technology, called "MAb'stract", to provide a means to discover, develop and produce a variety of biopharmaceuticals for the treatment of human diseases.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Goldman Sachs International has been appointed to act as global coordinator, lead manager and bookrunner of the initial public offering. In addition, a syndicate of banks has been formed to act as co-lead managers for the offering, comprising ING Barings and UBS Warburg. A copy of Crucell's prospectus, when available, may be obtained from Goldman, Sachs & Co., One Liberty Plaza, New York, NY 10006, Tel.+1-212-902 1171, ING Barings Amsterdam, Postbus 1800, Location code TR 0021, 1000 BV Amsterdam, The Netherlands, Tel.+31-20-563 8523 and UBS Warburg, 2 Finsbury Avenue, London, EC2M 2PG Tel. +44-20-7568 3523.
|
